Cabaletta Bio, Inc.

NasdaqGS:CABA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 135.81 M

Share Price

USD 1.51

Avg Daily Volume

2,077,588

Change (1 day)

1.34%

Change (1 year)

-80.03%

Change (YTD)

-33.48%

Cabaletta Bio, Inc. Long-Term Debt for the year ending July 09, 2025: N/A

Cabaletta Bio, Inc. Long-Term Debt is NA for the year ending July 09, 2025. Long-term debt is bebt obligations with maturities beyond one year.

Competitors

AbbVie Inc.

USD 189.77

ABBV

+2.14 1.14%

Novo Nordisk A/S

USD 70.59

NOVO-B.CO

+1.50 2.17%

Roche Holding AG

USD 342.36

RO.SW

+0.11 0.03%

Novartis AG

USD 122.54

NOVN.SW

+0.43 0.36%

Abbott Laboratories

USD 133.36

ABT

-0.34 -0.25%

AstraZeneca PLC

USD 140.42

AZN.L

+1.47 1.06%

Merck & Co., Inc.

USD 81.37

MRK

+0.47 0.58%

Thermo Fisher Scientific Inc.

USD 426.17

TMO

+7.47 1.78%

Amgen Inc.

USD 297.00

AMGN

+4.05 1.38%

Boston Scientific Corporation

USD 102.41

BSX

-1.42 -1.37%

Pfizer Inc.

USD 25.62

PFE

+0.38 1.51%

Gilead Sciences, Inc.

USD 111.06

GILD

-0.72 -0.64%

Vertex Pharmaceuticals Incorporated

USD 466.36

VRTX

+6.95 1.51%

Sanofi

USD 97.70

SAN.PA

+1.18 1.22%

Bristol-Myers Squibb Company

USD 47.04

BMY

+0.55 1.18%

Chugai Pharmaceutical Co., Ltd.

USD 46.38

4519.T

-0.70 -1.48%

CSL Limited

USD 159.49

CSL.AX

-1.10 -0.69%

GSK plc

USD 19.20

GSK.L

+0.23 1.19%

Siemens Healthineers AG

USD 55.00

SHL.DE

+0.44 0.81%

Regeneron Pharmaceuticals, Inc.

USD 547.75

REGN

+9.64 1.79%

Key Data

Date	Long-Term Debt	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments